Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease

Neuropsychopharmacology

Volumn 15, Issue 2, 1996, Pages 163-170

  Raffaele, Kathleen C ^a,b   Asthana, Sanjay ^a   Berardi, Annamaria ^a   Haxby, James V ^a   Morris, P Pearse ^a   Schapiro, Mark B ^a   Soncrant, Timothy T ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Acetylcholine; Alzheimer's disease; Arecoline; Memory

Indexed keywords

ARECOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DEPTH PERCEPTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MENTAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 0030222225     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00179-H     Document Type: Article

References (51)

1. Ashe JH, Weinberger NM (1991): Acetylcholine modulation of cellular excitability via muscarinic receptors: Functional plasticity in auditory cortex. In Richardson RT (ed), Activation to Acquisition: Functional Aspects of the Basal Forebrain Cholinergic System. Boston, Birkhauser, pp 189-246
2. Asthana S, Raffaele KC, Berardi A, Greig NH, Haxby JV, Schapiro MB, Soncrant TT (1996) (in press): Treatment of Alzheimer's disease by continuous intravenous infusion of physostigmine. Alz Dis Assoc Disord
3. Bassant MH, Baleyte JM, Lamour Y (1990): Effects of acetylcholine on single cortical somatosensory neurons in the unanesthetized rat. Neuroscience 39:189-197
4. Becker RE, Giacobini E (1988): Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: Clinical, pharmacological, and therapeutic aspects. Drug Devel Res 12:163-195
5. Benton AL (1974): Revised Visual Retention Test Manual. New York, Psychological Corporation
6. Benton AL, Hamsher KD (1976): Multilingual Examination. Iowa City, University of Iowa
7. Berardi A, Haxby JV, Grady CL, Rapoport SI (1991): Asymmetries of brain glucose metabolism and memory in healthy aging. Dev Neuropsychol 7:87-97
8. Boller F, Vignolo LA (1966): Latent sensory aphasia in hemisphere-damaged patients: An experimental study with the Token Test. Brain 89:815-831
9. Brinkman SD, Gershon S (1983): Measurement of cholinergic drug effects on memory in Alzheimer's disease. Neurobiol Aging 4:139-145
10. Buschke H (1973): Selective reminding for analysis of memory and learning. J Verb Learn Verb Behav 12:543-550
11. Butters N, Granholm E, Salmon DP, Grant I (1987): Episodic and semantic memory: A comparison of amnesic and demented patients. J Clin Exp Neuropsychol 9:479-497
12. Callaway E, Halliday R, Naylor H (1992): Cholinergic activity and constraints on information processing. Biological Psychol 33:1-22
13. Crews FT, Meyer EM, Gonzales RA, Theiss C, Otero DH, Larsen K, Raulli R, Calderini G (1986): Presynaptic and postsynaptic approaches to enhancing central cholinergic neurotransmission. In Crook T, Bartus RT, Ferris S, Gershon S (eds), Treatment Development Strategies for Alzheimer's Disease. Madison, CT, Mark Powley Associates, pp 385-419
14. Davis KL, Mohs RC (1982): Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiat 9:1421-1424
15. Day J, Damsma G, Fibiger HC (1991): Cholinergic activity in the rat hippocampus, cortex and striatum correlates with locomotor activity: An in vivo microdialysis study. Pharmacol Biochem Behav 38:723-729
16. Durkin T (1989): Central cholinergic pathways and learning and memory processes: Presynaptic aspects. Comp Biochem Physiol 93A:273-280
17. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, Tacrine Study Group (1992): A controlled trial of tacrine in Alzheimer's disease. JAMA 268:2523-2529
18. Fibiger HC (1991): Cholinergic mechanisms in learning, memory and dementia: A review of recent evidence. Trends Neurosci 14:220-223
19. Fibiger HC, Damsma G, Day JC (1991): Behavioral pharmacology and biochemistry of central cholinergic neurotransmission. In Napier TC, Kalivas PW, Hanin I (eds), The Basal Forebrain. Advances in Experimental Medicine and Biology, vol 295. New York, Plenum, pp 399-414
20. Flicker C, Serby M, Ferris SH (1990): Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology 100:243-250
21. Folstein MF, Folstein SE, McHugh PR (1975): "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
22. Freedman SB, Harley EA, Iversen LL (1988): Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: The NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors. Br J Pharmacol 93:437-445
23. Freedman SB, Harley EA, Marwood RS, Patel S (1990): In vivo characterisation of novel efficacious muscarinic receptor agonists. Eur J Pharmacol 187:193-199
24. Geula C, Mesulam MM (1989): Cortical cholinergic fibers in aging and Alzheimer's disease: A morphometric study. Neurosci 33:469-481
25. Golden CJ (1978): The Stroop Color and Word Test: A Manual for Clinical and Experimental Uses. Chicago, Stoetling
26. Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI (1985): Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J Cereb Blood Flow Metab 5:193-200
27. Hollander E, Davidson M, Mohs RC, Horvath TB, Davis BM, Zemishlany Z, Davis KL (1985): RS 86 in the treatment of Alzheimer's disease: Cognitive and biological effects. Biol Psychiatry 22:1067-1078
28. Juliano SL, Ma W, Bear MF, Eslin D (1990): Cholinergic manipulation alters stimulus-evoked metabolic activity in cat somatosensory cortex. J Comp Neurol 297:106-120
29. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, Tacrine Study Group (1994): A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271:985-991
30. Levy A, Brandeis R, Treves TA, Meshulam Y, Mawassi F, Feiler D, Wengier A, Glikfeld P, Grunwald J, Dachir S, Rabey JM, Levy D, Korczyn AD (1994): Transdermal physostigmine in the treatment of Alzheimer's disease. Alz Dis Assoc Disord 8:15-21
31. McGeer PL (1984): Aging, Alzheimer's disease, and the cholinergic system. Can J Physiol Pharmacol 62:741-754
32. McKhann G, Drachman D, Holstein M, Katzman R, Price D, Stadlan EM (1984): Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurol 34:939-944
33. Messer WS, Ellerbrock B, Price M, Hoss W (1989): Autoradiographic analyses of agonist binding to muscarinic receptor subtypes. Biochem Pharmacol 38:837-850
34. Peterson SE, Fox PT, Posner MI, Mintun M, Raichle ME (1988): Positron emission tomographic studies of the cortical anatomy of single-word processing. Nature 331: 585-589
35. Raffaele K, Olton D, Annau Z (1990): Repeated exposure to diisopropylfluorophosphate (DFP) produces increased sensitivity to cholinergic antagonists in discrimination retention and reversal. Psychopharmacol 100:267-274
36. Raffaele KC, Berardi A, Asthana S, Morris P, Haxby JV, Soncrant TT (1991): Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacol Bull 27:315-319
37. Richardson RT, DeLong MR (1991): Functional implications of tonic and phasic activity changes in nucleus basalis neurons. In Richardson RT (ed), Activation to acquisition: Functional aspects of the basal forebrain cholinergic system. Boston, Birkhauser, pp 135-166
38. Rosen WG, Mohs RC, Davis KL (1984): A new rating scale for Alzheimer's disease. Am J Psychiatry 141:1356-1364
39. Roth M (1986): The association of clinical and neurological findings and its bearing on the classification and aetiology of Alzheimer's disease. Br Med Bull 42:42-50
40. Rupniak NMJ (1992): Profile of cholinomimetic drugs in primates: Status of screens for potential Alzheimer therapies. Drug Devel Res 27:77-88
41. Russell RW, Smith CA, Booth RA, Jenden DJ, Waite JJ (1986): Behavioral and physiological effects associated with changes in muscarinic receptors following administration of an irreversible cholinergic agonist (BM 123). Psychopharmacol 90:308-315
42. Sarter M, Bruno JP, Dudchenko P (1990): Activating the damaged basal forebrain cholinergic system: Tonic stimulation versus signal amplification. Psychopharmacol 101:1-17
43. SAS Institute, Inc. (1988): SAS/STAT Release 6.03 Edition, Cary, NC, SAS Institute, Inc.
44. Soncrant TT, Holloway HW, Rapoport SI (1985): Arecoline-induced elevations of regional cerebral metabolism in the conscious rat. Brain Res 347:205-216
45. Soncrant TT, Raffaele KC, Asthana S, Berardi A, Morris PP, Haxby JV (1993): Memory improvement without toxicity during chronic low dose intravenous arecoline in Alzheimer's disease. Psychopharmacology 112:421-427
46. Sunderland T, Tariot PN, Newhouse PA (1988): Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 13:371-389
47. Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, New-house PA, Murphy DL, Weingartner H (1988): Multiple-dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 45:901-905
48. Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR (1989): Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Am Geriatr Soc 37: 42-48
49. Wechsler DA (1955): Wechsler Adult Intelligence Scale. New York, Psychological Corporation
50. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982): Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215:1237-1239
51. Woolf NJ, Butcher LL (1991): The cholinergic basal forebrain as a cognitive machine. In Richardson RT (ed), Activation to acquisition: Functional aspects of the basal forebrain cholinergic system. Boston, Birkhauser, pp 347-380